Efficacy of Guhong injection versus Butylphthalide and Sodium Chloride Injection for mild ischemic stroke: A multicenter controlled study

Table 1 Number of subjects recruited at each center

Center	Experimental group (n = 198)	Control group (n = 201)	Total (n = 399)
Seventh Medical Center of PLA General Hospital	0	92	92
First Affiliated Hospital of Nanchang University	38	32	70
People’s Hospital of Liaoning Province	40	0	40
Cangzhou People’s Hospital	31	42	73
Second People’s Hospital of Huai’an	39	35	74
Ganyu District People’s Hospital of Lianyungang	50	0	50

Table 2 Baseline information of patients in the two groups

	Male (n, %)	Age (yr)	Height (cm)	Weight (kg)	Heart rate (beats/min)	Body temperature (℃)	Systolic pressure (mmHg)	Diastolic pressure (mmHg)
Experimental group (n = 198)	109 (55.3)	65.57 ± 10.47	164.83± 7.28	65.12 ± 9.191	76.9 ± 14.34	36.42 ± 0.33	147.48 ± 23.20	84.23 ± 14.00
Control group (n = 201)	132 (65.7)	64.87 ± 10.75	Missing	Missing	78.2 ± 15.80	36.43 ± 0.34	150.30 ± 24.11	84.57 ± 14.43
Statistic	4.46	0.42	0.23	0.28	0.52	0.04	1.44	0.567
P value	0.35	0.674	0.6313	0.5939	0.603	0.965	0.15	0.57

Table 3 Changes in baseline total National Institutes of Health stroke scale scores at each follow-up visit

	Experimental group (n = 198)	Control group (n = 201)	Rank-sum test	P value
Baseline (day 0)	3.40 ± 2.08	3.63 ± 2.72	0.495	0.621
Visit 1 (days 7 ± 2)	1.75 ± 2.03	2.34 ± 2.37	1.588	0.056
Relative to baseline	-1.67 ± 2.11	-1.25 ± 2.62	300.727	< 0.0001
Visit 2 (days 14 ± 2)	1.65 ± 1.90	2.45 ± 2.26	8.138	< 0.0001
Relative to baseline	-2.33 ± 2.33	-1.45 ± 2.36	222.404	< 0.0001
Visit 3 (days 21 ± 3)	2.33 ± 1.63	5.0 ± 3.54	2.207	0.016
Relative to baseline	-2.50 ± 2.32	-1.67 ± 4.12	16.19	< 0.0001

Table 4 Efficacy of medications in the two groups, n (%)

		Experimental group (n = 198)	Control group (n = 201)	χ2	P value
Visit 1 (days 7 ± 2)	Marked response	128 (64.64)	97 (48.26)	11.60	0.003
	Mild response	67 (33.84)	102 (50.75)
	No response	3 (1.51)	2 (0.99)
Visit 2 (days 14 ± 2)	Marked response	62 (74.7)	64 (45.4)	835.36	< 0.0001
	Mild response	21 (25.30)	75 (53.2)
	No response	0	2 (1.41)
Visit 3 (days 21 ± 3)	Marked response	4 (66.7)	2 (22.2)	887.40	< 0.0001
	Mild response	2 (33.3)	6 (66.7)
	No response	0 (0)	1 (11.1)
Visit 1 (days 7 ± 2)	Overall response	195 (98.48)	199 (99.01)	0.121	0.728
	No response	3 (1.52)	2 (0.99)
Visit 2 (days 14 ± 2)	Overall response	83 (100)	139 (98.59)	403.127	< 0.0001
	No response	0	2 (1.41)
Visit 3 (days 21 ± 3)	Overall response	6 (100)	8 (88.89)	9.63	0.0019
	No response	0	1 (11.11)

Table 5 Distribution of modified Rankin scale scores in the two groups

	Experimental group (n = 198)	Control group (n = 201)	Rank-sum test	P value
Baseline			1.88	0.3903
No symptom	15 (7.6)	48 (23.6)
No significant disability	132 (66.7)	95 (47.8)
Mild disability	38 (19.2)	41 (20.2)
Moderate disability	7 (3.5)	9 (4.4)
Moderately severe disability	6 (3.0)	8 (3.9)
Severe disability	0	0
Visit 1 (days 7 ± 2)			11.66154	0.020
No symptom	119 (60.1)	89 (44.8)
No significant disability	57 (28.8)	86 (42.4)
Mild disability	16 (8.1)	17 (8.4)
Moderate disability	6 (3.0)	7 (3.4)
Moderately severe disability	0	2 (1.0)
Severe disability	0	0
Visit 2 (days 14 ± 2)			6.098	0.192
No symptom	46 (55.4%)	59 (41.8%)
No significant disability	29 (34.9%)	62 (44.0%)
Mild disability	8 (9.6%)	15 (10.6%)
Moderate disability	0	4 (2.8%)
Moderately severe disability	0	1 (0.7%)
Severe disability	0	0

Table 6 Propensity score matching between the experimental group and control group

Factors	Before propensity score; Experimental group (n = 198)	Control group (n = 201)	P value	After propensity score; Experimental group (n = 111)	Control group (n = 111)	P value
Combined medication based on vitamins	-0.331	0.288	0.25	0.375	0.91	0.34
Combined medication based on Chinese patent medicine	0.539	0.31	0.082	0.147	0.17	0.68
Combined medication based on neurotrophic agents	0.575	0.225	0.011	-0.193	0.467	0.494
Combined medication based on free-radical scavengers	-1.823	0.245	0	-0.017	0.003	0.955
Concomitant medication for respiratory diseases	-1.182	0.44	0.007	-0.032	0.003	0.953
Concomitant medication for genitourinary diseases	-0.638	0.557	0.252	0.279	0.197	0.657
Concomitant medication for coronary heart disease	0.414	0.423	0.328	0.512	1.085	0.298